Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

Diabetes Technology and Therapeutics

Volumn 19, Issue 3, 2017, Pages 155-163

  Garg, Satish K ^a   Weinzimer, Stuart A ^b   Tamborlane, William V ^b   Buckingham, Bruce A ^c   Bode, Bruce W ^d   Bailey, Timothy S ^e   Brazg, Ronald L ^f   Ilany, Jacob ^g   Slover, Robert H ^a   Anderson, Stacey M ^h   Bergenstal, Richard M ⁱ   Grosman, Benyamin ^j   Roy, Anirban ^j   Cordero, Toni L ^j   Shin, John ^j   Lee, Scott W ^j   Kaufman, Francine R ^j  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b YALE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d ATLANTA DIABETES ASSOCIATES   (United States)

^e AMCR Institute   (United States)

^f Rainier Clinical Research Center   (United States)

^g SHEBA MEDICAL CENTER   (Israel)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ INTERNATIONAL DIABETES CENTER   (United States)

^j Medtronic   (United States)

more..

Author keywords

Continuous glucose monitoring; Hybrid closed loop; Hyperglycemia; Hypoglycemia; Insulin pump; Sensor; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DEVICE SAFETY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HUMAN; HYBRID CLOSED LOOP INSULIN DELIVERY SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; TREATMENT DURATION; AGED; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; INSULIN INFUSION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015319338     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2016.0421     Document Type: Article

References (39)

1. Miller KM, Foster NC, Beck RW, et al.: Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978.
2. Weinzimer SA, Steil GM, Swan KL, et al.: Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-939.
3. Trevitt S, Simpson S, Wood A: Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016; 10:714-723.
4. Kovatchev BP, Breton M, Man CD, et al.: In silico pre-clinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009;3:44-55.
5. Atlas E, Nimri R, Miller S, et al.: MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072-1076.
6. Breton M, Farret A, Bruttomesso D, et al.: Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230-2237.
7. Buckingham BA, Beck RW, Ruedy KJ, et al.: Diabetes Research in Children Network Study Group; Type 1 Diabetes TrialNet Study Group. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 2013;15: 401-408.
8. Castle JR, Engle JM, El Youssef J, et al.: Novel use of glucagon in a closed-loop system for prevention of hypo-glycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
9. O'Grady MJ, Retterath AJ, Keenan DB, et al.: The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35:2182-2187.
10. Russell SJ, El-Khatib FH, Nathan DM, et al.: Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148-2155.
11. Kovatchev BP, Renard E, Cobelli C, et al.: Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36: 1851-1858.
12. Nimri R, Muller I, Atlas E, et al.: Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014;15:91-99.
13. Phillip M, Battelino T, Atlas E, et al.: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833.
14. Kovatchev B, Cheng P, Anderson SM, et al.: Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther 2016 [DOI: 10.1089/dia.2016.0333].
15. Nimri R, Muller I, Atlas E, et al.: MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014; 37:3025-3032.
16. Tauschmann M, Allen JM, Wilinska ME, et al.: Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2016;39:1168-1174.
17. Thabit H, Elleri D, Leelarathna L, et al.: Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab 2015;17:452-458.
18. Thabit H, Tauschmann M, Allen JM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015; 373:2129-2140.
19. Steil GM, Palerm CC, Kurtz N, et al.: The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402-1408.
20. Roy A, Grosman B, Parikh N, et al.: Physiological and technical stress test for Medtronic's artificial pancreas system in a supervised outpatient setting. Diabetes Technol Ther 2015;17:A17.
21. Ly TT, Roy A, Grosman B, et al.: Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 2015;38:1205-1211.
22. Ly TT, Weinzimer SA, Maahs DM, et al.: Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatr Diabetes 2016;10.1111/pedi.12399.
23. Grosman B, Ilany J, Roy A, et al.: Hybrid closed-loop insulin delivery in type 1 diabetes during supervised outpatient conditions. J Diabetes Sci Technol 2016;10:708-713.
24. de Bock MI, Roy A, Cooper MN, et al.: Feasibility of outpatient 24-hour closed-loop insulin delivery. Diabetes Care 2015;38:e186-e187.
25. Bergenstal RM, Garg S, Weinzimer SA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016;316:1407-1408.
26. Ruiz JL, Sherr JL, Cengiz E, et al.: Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol 2012;6:1123-1130.
27. Dasari PS, Gandomani BS, Teague AM, et al.: Glycemic variability is associated with markers of vascular stress in adolescents. J Pediatr 2016;172:47-55.
28. Jung HS: Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol Metab 2015; 30:167-174.
29. de Bock M, Dart J, Roy A, et al.: Exploration of the performance of a hybrid closed loop insulin delivery algorithm that includes insulin delivery limits designed to protect against hypoglycemia. J Diabetes Sci Technol 2016 [DOI: 10.1177/1932296816668876].
30. Brazg R, Christiansen M, Bode B, et al.: Accuracy of a fourth-generation glucose sensor throughout its functional life. Diabetes 2016;65:A226.
31. Bailey TS, Ahmann A, Brazg R, et al.: Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther 2014;16:277-283.
32. Keenan DB, Mastrototaro JJ, Zisser H, et al.: Accuracy of the enlite 6-day glucose sensor with Guardian and Veo calibration algorithms. Diabetes Technol Ther 2012;14: 225-231.
33. Bergenstal RM, Klonoff DC, Garg SK, et al.: Threshold-based insulin-pump interruption for reduction of hypogly-cemia. N Engl J Med 2013;369:224-232.
34. Choudhary P, Olsen BS, Conget I, et al.: Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18:288-291.
35. Kovatchev BP, Renard E, Cobelli C, et al.: Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014;37: 1789-1796.
36. Russell SJ, El-Khatib FH, Sinha M, et al.: Outpatient gly-cemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325.
37. van Bon AC, Luijf YM, Koebrugge R, et al.: Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther 2014;16:131-136.
38. Tauschmann M, Allen JM, Wilinska ME, et al.: Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial. Diabetes Care 2016;39:2019-2025.
39. Food and Drug Administration, Center for Devices and Radiological Health: MiniMed 670G System approval letter, September 28, 2016. www.accessdata.fda.gov/cdrh-docs/ pdf16/P160017a.pdf (accessed January 11, 2017).